Pipeline › retatrutide

retatrutide

Not FDA-approved, and in phase 3 development, not authorised in the European Union. 7 active trials, the next due to complete 2026-10.

GIP/GLP-1/glucagon agonist, SC, from Eli Lilly. Every figure below is taken directly from ClinicalTrials.gov, Drugs@FDA, the FDA Drug Shortage Database, the EMA register or Europe PMC, and re-checked every four hours.

Status: phase3
Target: GIP/GLP-1/glucagon
Route: SC
Sponsor: Eli Lilly
First FDA approval: Not approved
EU authorisation: Not authorised
Active trials: 7 (6 in phase 3)
Participants enrolled: 12,699
Trials with a reporting date: 7
Approved FDA submissions: 0

When these trials report

When trials are due to report, by quarter — hover a bar for the count. These dates are filed by the sponsor and often move.

Next 7 of 7 active trials by estimated primary completion.

Est. completion	Trial	Sponsor	Phase	Participants
2026-10	Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) NCT06297603 · Change from Baseline in Hemoglobin A1c (HbA1c) (%)	Eli Lilly and Company	P3	320
2027-03-14	Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight NCT07467447 · Mean percent change in body weight from randomization/baseline to Week 24.	Hudson Biotech	P2	300
2027-07	A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight NCT07232719 · Percent Change from Baseline in Body Weight	Eli Lilly and Company	P3	250
2027-09	A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain NCT07035093 · Change from Baseline in Pain Intensity Per Numeric Rating Scale	Eli Lilly and Company	P3	586
2028-04	A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity NCT06859268 · Percent Change from Baseline in Body Weight	Eli Lilly and Company	P3	643
2028-10	A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight NCT07357415 · Percent Change from Baseline in Body Weight	Eli Lilly and Company	P3	600
2029-02	The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) NCT06383390 · Time to First Occurrence of Composite Endpoints	Eli Lilly and Company	P3	10,000

Indications under study

Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD); Chronic Low Back Pain (CLBP); Obesity; Overweight; Type 2 Diabetes.

Recent papers

Published	Title	Journal
2026-12-01	Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis Carneiro GRA, da Costa Nunes IK, Dos Santos Cardoso GR, Dos Santos PF, Padilha MC, Nogueira FCS, Pereira HMG.	Rapid Commun Mass Spectrom
2026-10-09	Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain Rubin R.	JAMA
2026-10-07	Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide Buzzi RM, Huber LC.	BMJ Case Rep
2026-10-01	Retatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2? Holst JJ.	Lancet
2026-10-01	Retatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest Wise J.	BMJ
2026-09-29	Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, Eyde S, Park SY, Ferro J, Johnson C, Taylor A.	Lancet
2026-09-29	Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, Ahmad NN, Murray M, Du Y, Makarova N, Giblin K, Schloot NC, Wang Y, TRIUMPH-1 Investigators.	N Engl J Med
2026-09-15	Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats Petersen J, Merrild C, Holm SK, Kurgan N, Hassan S, Mathiesen CV, Börchers S, Svendsen C, D'Anna S, Andersen NR, Klein AB, Fritzen AM, Deshmukh AS, Pers TH, Clemmensen C.	Nat Metab
2026-09-01	Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia Piatkowski T, Craven A, Cornell S, Ferris J.	Drug Alcohol Rev
2026-08-31	Potential Role of the Triple Receptor Agonist Retatrutide in Antipsychotic-Associated Metabolic Dysfunction Among Clozapine- and Olanzapine-Treated Schizophrenia Spectrum Disorders: A Narrative Review and Theoretical Framework Kaczynski MM, Zureikat RM, Kaczynski MR, Sitarz R, Karakuła-Juchnowicz H.	Biomedicines
2026-08-26	Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis Branine N.	Cureus
2026-08-17	Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes Ruotolo G, Harris C, Lin Y, Wilson JM, Pirro V, Duffin KL, Thomas MK, Hartman ML, Neill CO, Coskun T, Milicevic Z, Haupt A, Sattar N, Nicholls SJ.	Diabetes Obes Metab
2026-08-13	Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice Ding M, Li X, Wei Y, Wang J, Jiao B, Li C, Ma W, Peng Y, Shen J, Yu G, Gao C.	iScience
2026-08-07	Retatrutide: Obesity drug opens to "compassionate use" in US after speculation Trump took it Brown C.	BMJ
2026-08-01	Retatrutide effects on diabetic rats' cognition Ferreira J.	Lab Anim (NY)

Headlines

2026-10-02

Retatrutide Delivers Substantial Weight Loss in Type 2 Diabetes

MedPage Today

2026-10-14

What Is Retatrutide and When Could Weight-Loss Drug Be Publicly Available?

Newsweek

2026-10-17

retatrutide weight loss drug latest updates 2026

PhilSTAR Life

2026-10-13

Bootleg Retatrutide Deaths? PMOS and Dementia; Weight-Loss Drug to Be Discontinued

MedPage Today

Every retatrutide trial on file

All 14 registered trials of retatrutide, largest first. Each links to its own page and to the registry record.

Trial	Status	Phase	Participants
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) NCT06383390 · Eli Lilly and Company	Active, not recruiting	P3	10,000
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight NCT05929066 · Eli Lilly and Company	Completed	P3	2,335
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease NCT05882045 · Eli Lilly and Company	Completed	P3	1,946
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight NCT05929079 · Eli Lilly and Company	Completed	P3	1,152
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity NCT06859268 · Eli Lilly and Company	Active, not recruiting	P3	643
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight NCT07357415 · Eli Lilly and Company	Active, not recruiting	P3	600
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain NCT07035093 · Eli Lilly and Company	Active, not recruiting	P3	586
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) NCT06354660 · Eli Lilly and Company	Completed	P3	537
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee NCT05931367 · Eli Lilly and Company	Completed	P3	445
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight NCT04881760 · Eli Lilly and Company	Completed	P2	338
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) NCT06297603 · Eli Lilly and Company	Active, not recruiting	P3	320
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight NCT07467447 · Hudson Biotech	Recruiting	P2	300
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight NCT07232719 · Eli Lilly and Company	Active, not recruiting	P3	250
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes NCT05936151 · Eli Lilly and Company	Completed	P2	146